Atea Pharmaceuticals
AVIR
127 hedge funds and large institutions have $396M invested in Atea Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 36 increasing their positions, 42 reducing their positions, and 38 closing their positions.
1.5% more ownership
Funds ownership: 64.52% → 66.02% (+1.5%)
11% less funds holding
Funds holding: 143 → 127 (-16)
14% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 42
17% less capital invested
Capital invested by funds: $477M → $396M (-$81.1M)
26% less call options, than puts
Call options by funds: $4.06M | Put options by funds: $5.47M
39% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 38
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$13.9M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$6.55M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$6.43M |
| 4 |
BlackRock
New York
|
+$5.73M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$3.94M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
-$9.75M |
| 2 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$5.33M |
| 3 |
State Street
Boston,
Massachusetts
|
-$3.08M |
| 4 |
Voloridge Investment Management
Jupiter,
Florida
|
-$2.37M |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$2.05M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
151
Truist Financial
Charlotte,
North Carolina
| – | -$139K | -15,510 | Closed |
|
152
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
| – | -$135K | -15,111 | Closed |
|
|
NC
153
NinePointTwo Capital
Los Angeles,
California
| – | -$132K | -14,844 | Closed |
|
|
AIM
154
Aigen Investment Management
New York
| – | -$91K | -10,977 | Closed |
|
155
Marshall Wace
London,
United Kingdom
| – | -$44K | -4,949 | Closed |
|
156
Belvedere Trading
Chicago,
Illinois
| – | -$25K | -3,821 | Closed |
|
|
QT
157
Quantbot Technologies
New York
| – | -$29K | -3,313 | Closed |
|
|
EWM
158
Edge Wealth Management
New York
| – | -$4K | -500 | Closed |
|
|
CAL
159
Capital Advisors Ltd
Shaker Heights,
Ohio
| – | +$54 | +8 | New |
|
|
QC
160
Quent Capital
New York
| – | +$238 | +35 | New |
|
AVIR Hedge Fund Activity: Q1 2022 in Review
127 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q1 2022, worth a combined $396M — down 17% from $477M a quarter earlier.
Sellers outnumbered buyers: 38 funds closed out of AVIR and 23 opened new positions — a net loss of 15 holders — while 42 trimmed existing stakes and 36 added.
The largest buyer was Federated Hermes, opening a new position worth an estimated $13.9M. The largest seller was Schroder Investment Management Group, cutting an estimated $9.75M.
- 127 institutional investors held Atea Pharmaceuticals (AVIR) as of Q1 2022, down from 143 in Q4 2021.
- Funds reported $396M of Atea Pharmaceuticals stock for Q1 2022, down 17% quarter-over-quarter.
- 23 funds opened new Atea Pharmaceuticals positions in Q1 2022 and 38 closed out, a net change of -15 holders.
- The largest Atea Pharmaceuticals buyer in Q1 2022 was Federated Hermes, an estimated $13.9M added.
- The largest Atea Pharmaceuticals seller in Q1 2022 was Schroder Investment Management Group, an estimated $9.75M sold.
Based on aggregated 13F filings for Q1 2022.